BR112023026964A2 - Composto de sulfoximina e uso do mesmo - Google Patents
Composto de sulfoximina e uso do mesmoInfo
- Publication number
- BR112023026964A2 BR112023026964A2 BR112023026964A BR112023026964A BR112023026964A2 BR 112023026964 A2 BR112023026964 A2 BR 112023026964A2 BR 112023026964 A BR112023026964 A BR 112023026964A BR 112023026964 A BR112023026964 A BR 112023026964A BR 112023026964 A2 BR112023026964 A2 BR 112023026964A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- sulfoximin
- sulfoximine
- pharmaceutically acceptable
- specifically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110694497 | 2021-06-22 | ||
| CN202210002094 | 2022-01-04 | ||
| CN202210665753 | 2022-06-13 | ||
| PCT/CN2022/100435 WO2022268119A1 (zh) | 2021-06-22 | 2022-06-22 | 亚磺酰亚胺类化合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023026964A2 true BR112023026964A2 (pt) | 2024-03-12 |
Family
ID=84545187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023026964A BR112023026964A2 (pt) | 2021-06-22 | 2022-06-22 | Composto de sulfoximina e uso do mesmo |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240376093A1 (enExample) |
| EP (1) | EP4361138A4 (enExample) |
| JP (1) | JP2024526156A (enExample) |
| KR (1) | KR20240024906A (enExample) |
| CN (1) | CN117500796B (enExample) |
| AU (1) | AU2022298616A1 (enExample) |
| BR (1) | BR112023026964A2 (enExample) |
| CA (1) | CA3223641A1 (enExample) |
| IL (1) | IL309572A (enExample) |
| MX (1) | MX2023015440A (enExample) |
| TW (1) | TWI825800B (enExample) |
| WO (1) | WO2022268119A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120239699A (zh) * | 2022-12-22 | 2025-07-01 | 祐森健恒生物医药（上海）有限公司 | 一种吡啶多取代化合物的盐型、晶型及其制备方法 |
| WO2025186427A1 (en) * | 2024-03-08 | 2025-09-12 | Curia Spain, S.A.U. | Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3495358T (lt) * | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| CN111936486B (zh) * | 2018-03-22 | 2023-09-22 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物 |
| JP7631193B2 (ja) * | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| AU2019373203B2 (en) * | 2018-10-30 | 2024-10-24 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| CN213366611U (zh) * | 2018-11-05 | 2021-06-04 | 深圳市优行新能源有限公司 | 光伏组件 |
| SG11202108162SA (en) * | 2019-01-30 | 2021-08-30 | Bristol Myers Squibb Co | Amide-disubstituted pyridine or pyridazine compounds |
| AU2021254764A1 (en) * | 2020-04-14 | 2022-11-03 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| KR20230004771A (ko) * | 2020-04-28 | 2023-01-06 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물 |
| TW202227430A (zh) * | 2020-11-17 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
-
2022
- 2022-06-22 CA CA3223641A patent/CA3223641A1/en active Pending
- 2022-06-22 US US18/573,074 patent/US20240376093A1/en active Pending
- 2022-06-22 EP EP22827611.9A patent/EP4361138A4/en active Pending
- 2022-06-22 CN CN202280043560.8A patent/CN117500796B/zh active Active
- 2022-06-22 AU AU2022298616A patent/AU2022298616A1/en active Pending
- 2022-06-22 TW TW111123283A patent/TWI825800B/zh active
- 2022-06-22 MX MX2023015440A patent/MX2023015440A/es unknown
- 2022-06-22 WO PCT/CN2022/100435 patent/WO2022268119A1/zh not_active Ceased
- 2022-06-22 IL IL309572A patent/IL309572A/en unknown
- 2022-06-22 BR BR112023026964A patent/BR112023026964A2/pt unknown
- 2022-06-22 JP JP2023578894A patent/JP2024526156A/ja active Pending
- 2022-06-22 KR KR1020247001056A patent/KR20240024906A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117500796A (zh) | 2024-02-02 |
| US20240376093A1 (en) | 2024-11-14 |
| WO2022268119A1 (zh) | 2022-12-29 |
| EP4361138A4 (en) | 2025-05-21 |
| IL309572A (en) | 2024-02-01 |
| CN117500796B (zh) | 2026-03-27 |
| CA3223641A1 (en) | 2022-12-29 |
| TW202315869A (zh) | 2023-04-16 |
| KR20240024906A (ko) | 2024-02-26 |
| EP4361138A1 (en) | 2024-05-01 |
| AU2022298616A1 (en) | 2024-01-18 |
| MX2023015440A (es) | 2024-04-29 |
| TWI825800B (zh) | 2023-12-11 |
| JP2024526156A (ja) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| BR112022012585A2 (pt) | Inibidores de formas mutantes de egfr | |
| BR112021022105A2 (pt) | Inibidores de cdk | |
| MX2024008987A (es) | Derivado de heteroaril-pireno sustituido por anillo puenteado, y uso del mismo. | |
| CO2023015419A2 (es) | Compuesto de péptido corto de prolina modificado con anillo y uso del mismo | |
| EP4335439A3 (en) | Compounds | |
| BRPI0517343A (pt) | derivados de betulina, preparação destes e uso dos mesmos | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| BR112012027373A2 (pt) | composição pesticida e seu uso | |
| BR112015024075A2 (pt) | compostos de piridinilpirazoloquinolina | |
| BRPI0814957B8 (pt) | composto, agente farmacêutico, e, uso do composto | |
| BR112017011316A2 (pt) | derivados heterocíclicos e uso destes | |
| BRPI0621386B8 (pt) | composição farmacêutica para o uso externo | |
| BR112017006253A2 (pt) | novos compostos | |
| BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
| BR112023026964A2 (pt) | Composto de sulfoximina e uso do mesmo | |
| BR112015030399A2 (pt) | derivados heterocíclicos e uso dos mesmos | |
| EA202192134A1 (ru) | Амидзамещенные гетероциклические соединения | |
| MXPA05013652A (es) | Modulador del receptor canabinoide. | |
| MX2024003130A (es) | Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma. | |
| CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. | |
| PH12020552261A1 (en) | Proteasome activity enhancing compounds | |
| AR114270A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmacéutico | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| BR112017006150A2 (pt) | composição aquosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: USYNOVA PHARMACEUTICALS LTD. (CN) |